Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis
This article explains general peptide reconstitution principles, UK regulatory status, and critical safety considerations it does not constitute clinical advice or endorse self-administration
The review is being carried out in the context of a signal procedure
Judgements for risk of bias in each domain were categorized as low, moderate or high
Do not use during pregnancy, active bleeding, pelvic infection, or immediately after gynecologic surgery unless specifically cleared
Worth knowing up front: in our experience, almost none of these patients have it covered by insurance for diabetes use, so well go over the real out-of-pocket cost with you before prescribing